2024年4月24日，浙江大学医学院附属第一医院/良渚实验室黄河/胡永仙/王东睿/张鸿声等团队在国际顶尖医学期刊《新英格兰医学杂志》（NEJM）发表了题为：Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis的临床研究论文。该研究在10例复发或难治性CD7阳性白血病或淋巴瘤患者中测试了一种...
[1] HU Y, ZHANG M, YANG T, et al. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis [J]. N Engl J Med, 2024, 390(16): 1467-80. [2] BLAISE D. CAR as Booster to Launch Allogen...
不采取GVHD预防策略的CD7 CAR T细胞疗法和异基因HSCT序贯方案 Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis Abstract Background:Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to ...
1. Hu Y, Zhang M, Yang T, et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. New Engl J Med. Published online April 24, 2024. doi:10.1056/NEJMoa2313812 2. CD7 CAR-T bridging t...
2024年4月25日,顶级学术期刊The New England Journal of Medicine发表浙江大学医学院附属第一医院黄河/胡永仙团队最新研究成果“Sequential CD7 CAR-T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis”[1]。研究首次提出CD7 CAR-T与异基因造血干细胞移植序贯治疗这一新颖的治疗策略。来自浙江大学医学院附属...
This study aimed to develop and evaluate a novel dual-target CD5-CD7 CAR-T-cell therapy as a preconditioning strategy for epitope-edited allogeneic HSCT, with the goal of establishing a novel treatment for R/R T-ALL. Methods: Leveraging established methodologies, we engineered Tan5-7 CAR-T ...
近日,浙江大学医学院附属第一医院/良渚实验室黄河/胡永仙/王东睿/张鸿声等团队在国际顶尖医学期刊《新英格兰医学杂志》(NEJM)发表了题为:Sequential CD7 CAR-T Therapy and Allo-HSCT without GvHD-prophylaxis Drugs的临床研究论文。该研究首次提出CD7 CAR-T与异基因造血干细胞移植序贯治疗的一体化策略,无需传统的清...
近日,高博医学(血液病)北京研究中心北京高博博仁医院吴彤主任团队李智慧主任的一项题为“Donor CD7 CAR-T bridging allogeneic hematopoietic stem cell transplantation for T-cell hematological malignancy”的前瞻性研究发表于Transplantation and Cellular Therapy上(图1)。值得一提的是,团队“CD7 CAR-T桥接异...
pre-HSCT myeloablation and graft-versus-host disease (GVHD) prophylaxis agents have toxic effects and could eradicate residual CAR T cells and compromise antitumor effects. Whether the integration of CAR T-cell therapy and allogeneic HSCT can preserve CAR T-cell function and improve tumor control ...
The result suggests that CD7 CAR T-cell therapy is an encouraging approach for the treatment of CD7 positive r/r AML. Abbreviations AML: Acute myeloid leukemia; Allo-HSCT: Allogeneic hematopoietic stem cell transplantation; BM: Bone marrow; CAR: Chimeric antigen receptor; CR: Complete ...